These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

679 related items for PubMed ID: 18570858

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D.
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [Abstract] [Full Text] [Related]

  • 5. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
    Heinicke T, Wardelmann E, Sauerbruch T, Tschampa HJ, Glasmacher A, Palmedo H.
    Anticancer Res; 2005 Jan; 25(6C):4591-4. PubMed ID: 16334147
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
    Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA.
    AJR Am J Roentgenol; 2004 Dec; 183(6):1619-28. PubMed ID: 15547201
    [Abstract] [Full Text] [Related]

  • 8. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
    Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, Guillou L, Elsig V, Stupp R, Delaloye AB, Leyvraz S.
    J Clin Oncol; 2009 Jan 20; 27(3):439-45. PubMed ID: 19064982
    [Abstract] [Full Text] [Related]

  • 9. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
    Jager PL, Gietema JA, van der Graaf WT.
    Nucl Med Commun; 2004 May 20; 25(5):433-8. PubMed ID: 15100500
    [Abstract] [Full Text] [Related]

  • 10. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
    Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA.
    J Nucl Med; 2012 Apr 20; 53(4):567-74. PubMed ID: 22381410
    [Abstract] [Full Text] [Related]

  • 11. F-18 FDG PET imaging in gastrointestinal stromal tumor.
    Reddy MP, Reddy P, Lilien DL.
    Clin Nucl Med; 2003 Aug 20; 28(8):677-9. PubMed ID: 12897659
    [Abstract] [Full Text] [Related]

  • 12. [Early response to treatment with Glivec detected with 18F-FDG PET in a patient with gastrointestinal stromal tumor].
    Delgado Bolton RC, Ortega Candil A, Pérez Castejón MJ, Garcerant M, Cabrera Martín MN, Lapeña Gutiérrez L, Carreras Delgado JL.
    Rev Esp Med Nucl; 2008 Aug 20; 27(2):112-7. PubMed ID: 18367049
    [Abstract] [Full Text] [Related]

  • 13. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
    Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, Schnyder P, Luthi F, von Schulthess GK, Leyvraz S.
    Eur J Nucl Med Mol Imaging; 2005 Feb 20; 32(2):153-62. PubMed ID: 15690223
    [Abstract] [Full Text] [Related]

  • 14. Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging.
    Zincirkeser S, Sevinc A, Kalender ME, Camci C.
    World J Gastroenterol; 2007 Apr 21; 13(15):2261-2. PubMed ID: 17465516
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate.
    Abhyankar SA, Nair N.
    Clin Nucl Med; 2008 Mar 21; 33(3):213-4. PubMed ID: 18287851
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
    Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, O'Day S, Kim K, Hodi FS, Van den Abbeele AD.
    Cancer Imaging; 2014 Nov 12; 14(1):30. PubMed ID: 25609545
    [Abstract] [Full Text] [Related]

  • 19. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
    Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, van den Borne B, Cole P, Sciot R, Dumez H, Silberman S, Mortelmans L, van Oosterom A.
    Eur J Cancer; 2003 Sep 12; 39(14):2012-20. PubMed ID: 12957455
    [Abstract] [Full Text] [Related]

  • 20. Esophageal gastrointestinal stromal tumor: report of 7 patients.
    Shinagare AB, Zukotynski KA, Krajewski KM, Jagannathan JP, Butrynski J, Hornick JL, Ramaiya NH.
    Cancer Imaging; 2012 Apr 27; 12(1):100-8. PubMed ID: 22542728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.